A general company introduction,
UEG Medical Group is invested by UEG Hongkong, mainly focus on Dental Imaging, Surgical Navigation, Surgical equipment, Bioactive Wound Healing,
The company does business worldwide and has +300 employees, visit its website for more information: www.uegmedical.com
The document discusses InnFocus, a surgical alternative for glaucoma. It is currently in its final FDA phase of trials and has CE Mark approval in Europe. Clinical trials show it is a safe and effective procedure that lowers intraocular pressure to below 14 mmHg in over 80% of patients. It provides over a 50% reduction in pressure from baseline and allows over 70% of patients to discontinue glaucoma medications after 3 years. The outcomes meet the standards for preventing vision loss progression according to the AGIS study. InnFocus represents a promising new treatment option for the large and growing glaucoma market.
1) Alcon and Google have partnered to develop "smart lens" technology to address unmet medical needs in eye care, such as treating cataracts, age-related macular degeneration, glaucoma, and presbyopia.
2) The collaboration aims to create glucose-sensing contact lenses to help diabetics manage their condition, and accommodating contact lenses or IOLs to restore near vision for presbyopes.
3) While smart lenses offer advantages like ease of use and data sharing, challenges include ensuring patient privacy as health data is collected and regulatory hurdles in approving new mobile medical devices.
This document summarizes corporate milestones and pipeline for Envisia Therapeutics, a company developing ophthalmic drug delivery systems. Key points include:
- The company was formed in 2013 and has raised $25 million in funding.
- They are developing long-acting biodegradable formulations of travoprost (ENV515) for glaucoma and difluprednate (ENV905) for post-cataract inflammation. Clinical trials are underway.
- Their PRINT technology platform can produce particles from 100nm to 1000um and is being used to develop extended release formulations of small molecules and biologics for front and back of the eye diseases.
The document discusses a small aperture intraocular lens (IOL) called the IC-8 IOL. It summarizes results from a post-market study showing the IC-8 IOL provides excellent visual acuity at far, intermediate, and near distances. Specifically, it found mean binocular uncorrected visual acuities of 20/20 or better for far and intermediate distances and 20/32 for near distances. The IC-8 IOL also demonstrated increased tolerance to uncorrected astigmatism compared to monofocal IOLs and maintained contrast sensitivity similar to monofocal IOLs. Additionally, the IC-8 IOL requires no special surgical technique for implantation and allows for ocular imaging and retinal procedures
This document discusses Jade's proprietary modified hyaluronic acid (CMHA-S) technology for ophthalmic applications. CMHA-S can be used as a standalone therapy for dry eye and corneal repair, or as a drug delivery vehicle for sustained release of small and large molecules to treat ocular diseases. Preclinical studies show CMHA-S eye drops improve dry eye symptoms compared to HA solution. The management team has extensive ophthalmic drug development experience. Near-term goals include clinical studies and regulatory approval of a CMHA-S ocular lubricant in the US and EU, as well as partnering opportunities and a Series A financing round to advance the CMHA-S platform.
The document outlines an agenda for seminars focused on different sectors including energy, chemistry, materials, healthcare and life science, and smart human capital. The dates and focus areas of each seminar are listed. Additionally, the document provides statistics on assignments per sector from 2007 to 2017, with the top sectors being production food, FMCG, services, pharma and healthcare, and construction. It encourages business transformation and upcycling through these seminars.
Gobiquity creates mobile diagnostic solutions to enable early detection and prevention of vision impairment through broad access. Their flagship product, GoCheck Kids, is a clinically validated mobile photoscreener that identifies Amblyopia Risk Factors. It has experienced rapid adoption, screening over 39,000 children across 25 states. Gobiquity plans to evolve the platform into a comprehensive digital diagnostics suite to address additional large vision markets like age-related macular degeneration and diabetic retinopathy that affect millions. Their uniquely positioned solutions leverage a hybrid team's expertise in mobile imaging, ophthalmology, and commercialization to improve outcomes through scalable and accurate telehealth services.
The document discusses InnFocus, a surgical alternative for glaucoma. It is currently in its final FDA phase of trials and has CE Mark approval in Europe. Clinical trials show it is a safe and effective procedure that lowers intraocular pressure to below 14 mmHg in over 80% of patients. It provides over a 50% reduction in pressure from baseline and allows over 70% of patients to discontinue glaucoma medications after 3 years. The outcomes meet the standards for preventing vision loss progression according to the AGIS study. InnFocus represents a promising new treatment option for the large and growing glaucoma market.
1) Alcon and Google have partnered to develop "smart lens" technology to address unmet medical needs in eye care, such as treating cataracts, age-related macular degeneration, glaucoma, and presbyopia.
2) The collaboration aims to create glucose-sensing contact lenses to help diabetics manage their condition, and accommodating contact lenses or IOLs to restore near vision for presbyopes.
3) While smart lenses offer advantages like ease of use and data sharing, challenges include ensuring patient privacy as health data is collected and regulatory hurdles in approving new mobile medical devices.
This document summarizes corporate milestones and pipeline for Envisia Therapeutics, a company developing ophthalmic drug delivery systems. Key points include:
- The company was formed in 2013 and has raised $25 million in funding.
- They are developing long-acting biodegradable formulations of travoprost (ENV515) for glaucoma and difluprednate (ENV905) for post-cataract inflammation. Clinical trials are underway.
- Their PRINT technology platform can produce particles from 100nm to 1000um and is being used to develop extended release formulations of small molecules and biologics for front and back of the eye diseases.
The document discusses a small aperture intraocular lens (IOL) called the IC-8 IOL. It summarizes results from a post-market study showing the IC-8 IOL provides excellent visual acuity at far, intermediate, and near distances. Specifically, it found mean binocular uncorrected visual acuities of 20/20 or better for far and intermediate distances and 20/32 for near distances. The IC-8 IOL also demonstrated increased tolerance to uncorrected astigmatism compared to monofocal IOLs and maintained contrast sensitivity similar to monofocal IOLs. Additionally, the IC-8 IOL requires no special surgical technique for implantation and allows for ocular imaging and retinal procedures
This document discusses Jade's proprietary modified hyaluronic acid (CMHA-S) technology for ophthalmic applications. CMHA-S can be used as a standalone therapy for dry eye and corneal repair, or as a drug delivery vehicle for sustained release of small and large molecules to treat ocular diseases. Preclinical studies show CMHA-S eye drops improve dry eye symptoms compared to HA solution. The management team has extensive ophthalmic drug development experience. Near-term goals include clinical studies and regulatory approval of a CMHA-S ocular lubricant in the US and EU, as well as partnering opportunities and a Series A financing round to advance the CMHA-S platform.
The document outlines an agenda for seminars focused on different sectors including energy, chemistry, materials, healthcare and life science, and smart human capital. The dates and focus areas of each seminar are listed. Additionally, the document provides statistics on assignments per sector from 2007 to 2017, with the top sectors being production food, FMCG, services, pharma and healthcare, and construction. It encourages business transformation and upcycling through these seminars.
Gobiquity creates mobile diagnostic solutions to enable early detection and prevention of vision impairment through broad access. Their flagship product, GoCheck Kids, is a clinically validated mobile photoscreener that identifies Amblyopia Risk Factors. It has experienced rapid adoption, screening over 39,000 children across 25 states. Gobiquity plans to evolve the platform into a comprehensive digital diagnostics suite to address additional large vision markets like age-related macular degeneration and diabetic retinopathy that affect millions. Their uniquely positioned solutions leverage a hybrid team's expertise in mobile imaging, ophthalmology, and commercialization to improve outcomes through scalable and accurate telehealth services.
ClearSightTM is an intraocular lens (IOL) platform designed to eliminate posterior capsule opacification (PCO) using SharkletTM technology. It has multiple issued patents and shown strong results in vivo, reducing cell migration by 80% and treatable PCO by 100% in studies. The ClearSightTM IOL addresses a significant problem in a large market by being the first IOL designed to eliminate PCO.
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
This presentation discusses Amblyotech's binocular treatment for amblyopia. Amblyopia affects 3% of the global population but current treatments like patching are only 25% effective. Amblyotech uses binocular video games calibrated for each patient to simultaneously stimulate both eyes, requiring the brain to accept input from both eyes. Their treatment showed 95% efficacy with just one hour daily for six weeks and no relapses, compared to patching which often fails after six months. The presentation outlines Amblyotech's intellectual property, partnerships with game developers and pediatric eye researchers, and experienced management team developing the first effective and compliant amblyopia treatment.
Icon Bioscience is developing improved ophthalmic drugs using its proprietary Verisome® technology to enable controlled, extended drug release with a single injection. Its lead product, IBI-10090, is a Verisome® formulation of dexamethasone for post-cataract surgery inflammation that has completed successful Phase 2 and 3 trials. Icon has a pipeline of additional ophthalmic products in development and expects to file an NDA for IBI-10090 in late 2015/early 2016, with potential to generate over $500 million in annual sales in the US alone. Icon aims to address large, unsatisfied ophthalmic markets through more convenient drug delivery with its Verisome® platform.
Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
- Second Sight develops the Argus II retinal prosthesis system which has been approved in the US, EU, Canada and Turkey to restore vision to blind patients.
- They have a large addressable market of over 8 million blind patients globally and are working to expand into additional causes of blindness like AMD.
- They have a strong patent portfolio, experienced leadership, and over $21 million in cash to support their commercialization and research efforts to develop new technologies like a cortical implant.
The document discusses micro-invasive glaucoma surgery (MIGS) and the CyPass micro-stent developed by Transcend Medical for treating glaucoma. It provides an overview of CyPass' development from 2005 to 2015, including pilot studies, ongoing clinical trials in the US and EU, and preliminary positive results showing reduced intraocular pressure. The document also discusses the potential of MIGS generally and CyPass specifically to provide an alternative between eye drop medications and more invasive surgeries like trabeculectomy for treating glaucoma.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
The document discusses five innovative health technologies that have been enabled by support from the Centre for Process Innovation. It describes technologies such as nanoparticles that can enhance radiotherapy treatment for cancer by generating free radicals without needing oxygen. It also discusses an automated device that can check if nasogastric tubes are correctly placed in patients' stomachs to eliminate human errors that have caused deaths. The document emphasizes how innovation centers help move research breakthroughs and ideas to commercialization to develop products that can improve health outcomes.
The document discusses accelerating innovation in ophthalmology. It notes that innovation requires focusing on patient needs, organizing for success, and making thoughtful choices regarding product innovation, disruptive platforms, delivery models, and other areas. Specific examples are provided of Alcon's innovations in cataract surgery, glaucoma surgery, vitreoretinal surgery, refractive surgery, and retinal pharmaceuticals. Alcon's collaboration with Google on non-invasive sensors and microchips is also mentioned as a potential disruptive platform.
Ophthalmology Innovation Showcase 1 - Mati TherapeuticsHealthegy
This document discusses a punctal plug drug delivery system called Evolute. It can deliver drugs to treat various ocular diseases like glaucoma, allergies, inflammation, and dry eye. Clinical trials showed excellent plug retention rates over 12 weeks. The system offers benefits like a flexible drug delivery profile, non-invasive application, steady drug elution unlike eye drops, and comfort. It is developing formulations of nepafenac, difluprednate, travoprost, olopatadine, and cyclosporine to treat conditions like post-cataract pain/inflammation and glaucoma. The company has a strong intellectual property position and plans upcoming clinical trials.
Alcon Corporate Presentation - short edition Sept 2016Yelena Fedorova
The document discusses Alcon's mission to discover new ways to enhance sight and improve people's lives. It notes that hundreds of millions of people worldwide are affected by eye diseases but that scientific and technological innovation is improving outcomes. Alcon operates in 74 countries and serves patients in over 140 countries, with a workforce of 16,000 people from 96 nationalities working to advance eye care.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Anteo Diagnostics ASX Spotlight Presentation March 2014Matt Sanderson
Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in diagnostics and life sciences. In 2013, Anteo achieved solid commercial progress including partnership agreements that are enhancing the prospects of becoming cash flow positive in 2014. Anteo is now focused on advancing near-term opportunities to generate licensing fees and royalties from Mix&Go and expanding into the large market for bioseparations.
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
Presentation from OIS@ASCRS 2016
Joseph Boorady, President & CEO
Video Presentaion:
https://www.youtube.com/watch?v=I_rVlB71VX4&index=32&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
EyeGate Pharma CEO Investor Presentation to BioCEO 2018Mike Garanzini
EyeGate Pharmaceuticals has two drug delivery platforms for eye disorders - an ocular bandage gel (OBG) eye drop and an iontophoresis delivery system. The OBG eye drop is a crosslinked hyaluronic acid gel that accelerates wound healing in the cornea. It has completed clinical trials showing accelerated re-epithelialization of corneal wounds. The iontophoresis system delivers corticosteroids into the eye using a mild electrical current, reducing the need for eye drops. Its lead product EGP-437 is being studied for inflammation after cataract surgery and uveitis, with clinical trials demonstrating trends of better outcomes than placebo.
Eye diseases remain a significant global problem, with glaucoma affecting an estimated 80 million people by 2020. Dry eye also has a high prevalence, affecting an estimated 15-18% of the general population or 30 million patients in the US. The eye care market is poised for growth driven by an aging population, expanded access to healthcare, and advances in drug delivery and devices. However, generics and cost controls pose barriers to growth. The pharmaceutical innovation ecosystem has expanded and diversified beyond large pharmaceutical companies, with biotech startups and regional players contributing more new drug approvals in recent years.
East Gate Medical is a medical equipment and supplies company based in Qatar that aims to provide innovative medical solutions throughout the region. It supplies public and private hospitals, clinics, pharmacies, and health centers with a wide range of products including aesthetic medicine, wound care, healthcare furniture, infection control, orthopedics, diabetes care, rehabilitation, surgery, and lab consumables. The company's mission is to improve patients' lives through high quality healthcare products and services at affordable prices.
Mega Medical and Scientific Technology was established in 2013 in Abu Dhabi, UAE to be a leading healthcare and scientific technology distributor in the region. It operates under Al Khaja Holding and has an extensive distribution network for medical equipment, pharmaceuticals, and other products. Mega Medical works with leading global healthcare companies to provide access to dynamic regional markets in the Middle East. The company's mission is to be the regional partner of choice for health and personal care solutions.
ClearSightTM is an intraocular lens (IOL) platform designed to eliminate posterior capsule opacification (PCO) using SharkletTM technology. It has multiple issued patents and shown strong results in vivo, reducing cell migration by 80% and treatable PCO by 100% in studies. The ClearSightTM IOL addresses a significant problem in a large market by being the first IOL designed to eliminate PCO.
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
This presentation discusses Amblyotech's binocular treatment for amblyopia. Amblyopia affects 3% of the global population but current treatments like patching are only 25% effective. Amblyotech uses binocular video games calibrated for each patient to simultaneously stimulate both eyes, requiring the brain to accept input from both eyes. Their treatment showed 95% efficacy with just one hour daily for six weeks and no relapses, compared to patching which often fails after six months. The presentation outlines Amblyotech's intellectual property, partnerships with game developers and pediatric eye researchers, and experienced management team developing the first effective and compliant amblyopia treatment.
Icon Bioscience is developing improved ophthalmic drugs using its proprietary Verisome® technology to enable controlled, extended drug release with a single injection. Its lead product, IBI-10090, is a Verisome® formulation of dexamethasone for post-cataract surgery inflammation that has completed successful Phase 2 and 3 trials. Icon has a pipeline of additional ophthalmic products in development and expects to file an NDA for IBI-10090 in late 2015/early 2016, with potential to generate over $500 million in annual sales in the US alone. Icon aims to address large, unsatisfied ophthalmic markets through more convenient drug delivery with its Verisome® platform.
Emmetrope Inc. is developing a line of accommodating intraocular lenses (IOLs) called ActaLens, ActaLens-Duo, and ActaLens-SC. The ActaLens models use a restrained hinge mechanism to allow movement of the optic when the eye focuses. Early clinical studies show the ActaLens providing over 0.5mm of movement and an estimated 0.5 diopters of accommodation. The dual optic ActaLens-Duo and shape changing ActaLens-SC are expected to provide even greater accommodation.
Medical device companies are looking to emerging markets like India, China, Brazil and Russia for growth due to challenges in developed markets from the global financial crisis. The emerging markets offer major opportunities due to their growing economies, expanding middle class populations and increasing healthcare spending. However, to successfully launch devices in these markets, companies will need to understand the local market needs, create customized and affordable products for each market, develop new collaborative R&D networks to drive innovation, and partner with local players to better serve customers.
- Second Sight develops the Argus II retinal prosthesis system which has been approved in the US, EU, Canada and Turkey to restore vision to blind patients.
- They have a large addressable market of over 8 million blind patients globally and are working to expand into additional causes of blindness like AMD.
- They have a strong patent portfolio, experienced leadership, and over $21 million in cash to support their commercialization and research efforts to develop new technologies like a cortical implant.
The document discusses micro-invasive glaucoma surgery (MIGS) and the CyPass micro-stent developed by Transcend Medical for treating glaucoma. It provides an overview of CyPass' development from 2005 to 2015, including pilot studies, ongoing clinical trials in the US and EU, and preliminary positive results showing reduced intraocular pressure. The document also discusses the potential of MIGS generally and CyPass specifically to provide an alternative between eye drop medications and more invasive surgeries like trabeculectomy for treating glaucoma.
Presentation from OIS@ASCRS 2016
Amar Sawhney, PhD, President, CEO & Chairman
Video Presentation:
https://www.youtube.com/watch?v=nGQzo6czij0&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=31
The document discusses five innovative health technologies that have been enabled by support from the Centre for Process Innovation. It describes technologies such as nanoparticles that can enhance radiotherapy treatment for cancer by generating free radicals without needing oxygen. It also discusses an automated device that can check if nasogastric tubes are correctly placed in patients' stomachs to eliminate human errors that have caused deaths. The document emphasizes how innovation centers help move research breakthroughs and ideas to commercialization to develop products that can improve health outcomes.
The document discusses accelerating innovation in ophthalmology. It notes that innovation requires focusing on patient needs, organizing for success, and making thoughtful choices regarding product innovation, disruptive platforms, delivery models, and other areas. Specific examples are provided of Alcon's innovations in cataract surgery, glaucoma surgery, vitreoretinal surgery, refractive surgery, and retinal pharmaceuticals. Alcon's collaboration with Google on non-invasive sensors and microchips is also mentioned as a potential disruptive platform.
Ophthalmology Innovation Showcase 1 - Mati TherapeuticsHealthegy
This document discusses a punctal plug drug delivery system called Evolute. It can deliver drugs to treat various ocular diseases like glaucoma, allergies, inflammation, and dry eye. Clinical trials showed excellent plug retention rates over 12 weeks. The system offers benefits like a flexible drug delivery profile, non-invasive application, steady drug elution unlike eye drops, and comfort. It is developing formulations of nepafenac, difluprednate, travoprost, olopatadine, and cyclosporine to treat conditions like post-cataract pain/inflammation and glaucoma. The company has a strong intellectual property position and plans upcoming clinical trials.
Alcon Corporate Presentation - short edition Sept 2016Yelena Fedorova
The document discusses Alcon's mission to discover new ways to enhance sight and improve people's lives. It notes that hundreds of millions of people worldwide are affected by eye diseases but that scientific and technological innovation is improving outcomes. Alcon operates in 74 countries and serves patients in over 140 countries, with a workforce of 16,000 people from 96 nationalities working to advance eye care.
Anteo Technologies - New York presentation 2015Matt Sanderson
- Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in healthcare, life sciences, and other industries.
- Mix&Go is a universal double-sided molecular coating that gently but strongly binds biomolecules to synthetic surfaces, addressing challenges in test miniaturization and cost reduction.
- Anteo's growth strategy includes licensing its intellectual property, expanding its coating technologies and applications, developing product pipelines that demonstrate Mix&Go's uses, exploring new market opportunities, and acquiring synergistic assets.
Anteo Diagnostics ASX Spotlight Presentation March 2014Matt Sanderson
Anteo Diagnostics is an Australian biotechnology company that develops proprietary surface coatings called Mix&Go for use in diagnostics and life sciences. In 2013, Anteo achieved solid commercial progress including partnership agreements that are enhancing the prospects of becoming cash flow positive in 2014. Anteo is now focused on advancing near-term opportunities to generate licensing fees and royalties from Mix&Go and expanding into the large market for bioseparations.
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
Presentation from OIS@ASCRS 2016
Joseph Boorady, President & CEO
Video Presentaion:
https://www.youtube.com/watch?v=I_rVlB71VX4&index=32&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw
EyeGate Pharma CEO Investor Presentation to BioCEO 2018Mike Garanzini
EyeGate Pharmaceuticals has two drug delivery platforms for eye disorders - an ocular bandage gel (OBG) eye drop and an iontophoresis delivery system. The OBG eye drop is a crosslinked hyaluronic acid gel that accelerates wound healing in the cornea. It has completed clinical trials showing accelerated re-epithelialization of corneal wounds. The iontophoresis system delivers corticosteroids into the eye using a mild electrical current, reducing the need for eye drops. Its lead product EGP-437 is being studied for inflammation after cataract surgery and uveitis, with clinical trials demonstrating trends of better outcomes than placebo.
Eye diseases remain a significant global problem, with glaucoma affecting an estimated 80 million people by 2020. Dry eye also has a high prevalence, affecting an estimated 15-18% of the general population or 30 million patients in the US. The eye care market is poised for growth driven by an aging population, expanded access to healthcare, and advances in drug delivery and devices. However, generics and cost controls pose barriers to growth. The pharmaceutical innovation ecosystem has expanded and diversified beyond large pharmaceutical companies, with biotech startups and regional players contributing more new drug approvals in recent years.
East Gate Medical is a medical equipment and supplies company based in Qatar that aims to provide innovative medical solutions throughout the region. It supplies public and private hospitals, clinics, pharmacies, and health centers with a wide range of products including aesthetic medicine, wound care, healthcare furniture, infection control, orthopedics, diabetes care, rehabilitation, surgery, and lab consumables. The company's mission is to improve patients' lives through high quality healthcare products and services at affordable prices.
Mega Medical and Scientific Technology was established in 2013 in Abu Dhabi, UAE to be a leading healthcare and scientific technology distributor in the region. It operates under Al Khaja Holding and has an extensive distribution network for medical equipment, pharmaceuticals, and other products. Mega Medical works with leading global healthcare companies to provide access to dynamic regional markets in the Middle East. The company's mission is to be the regional partner of choice for health and personal care solutions.
In over 60 countries, patients, doctors and partners alike depend on Auxein Medical to move forward. Every orthopaedic implant that we manufacture is built according to the highest quality standards. We take special pride in our dedicated team of experts that makes sure we stay in line with the stringent norms set by ISO 13485 2003, CE and US FDA 510k – a feat few in the industry have achieved.
In just seven years since inception the distinguishable quality and value advantage delivered by our generic orthopaedic implants has earned us the credibility to afford a rapidly expanding customer base, opportunities to provide OEM services to leading names in the industry as well as the confidence of the medical community at large.
Upon a strong foundation of proven customer satisfaction we are now building a world of exciting possibilities in R&D, innovation, customisation and education.
RD Medical is a company that designs and manufactures spinal fixation systems and implants. It was founded by mechanical and materials engineers, along with clinical experts. The company supplies innovative, high-quality products to the biomedical industry as an OEM partner. PRODORTH products are designed, manufactured, and developed in-house. The company aims to provide top-notch, detailed products to contribute to successful surgeries and patient outcomes. It works to satisfy the need for high-quality, fast-supplied products in the medical sector.
medical disposables -gloves,nonwovens,plastic disposables and sterilization p...倩倩 郭
There are disposable gloves,nonwoven disposables,plastic disposables and sterilization pouches in intco medical.
Contact:Lynette Guo
Email:lynetteguo@intco,com,cn
Phone:+86-34978818-1118
Europe's Top 5 Medical Device Companies to Watch in 2023.pdfinsightscare
The latest edition of Insights Care, Europe’s Top 5 Medical Device Companies to Watch in 2023, sheds light on the prominent leader, John O’Dea, CEO of Palliare.
Norman Broadhurst is a proven medical sales professional with over 25 years of experience selling medical devices, surgical instruments, and other products. He has a strong track record of exceeding sales targets and growing business. His resume highlights his career history working in sales roles of increasing responsibility, with achievements like negotiating cost savings, introducing new products, and winning tenders. He provides references from previous employers.
This document provides an overview of Schölly Fiberoptic GmbH's medical catalogue. It describes their products for endoscopy, including arthroscopes ranging from 1.7mm to 4mm in diameter, trocar sleeves, hand instruments, and an arthroscopy pump. The document highlights their experience in medical applications over 30+ years and commitment to quality and ethics. It also provides an outline of their corporate history and focus on visualization technology.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
The document proposes developing an affordable portable ultrasound device to enable widespread screening. It would benefit patients through early detection and be convenient for doctors to use like a stethoscope. The founders aim to market the device to various medical specialties. It outlines the product, team, sales strategy, target customers, costs, revenue projections, potential partners, funding needs, and risks. The goal is for the device to become profitable within 4 years of development and regulatory approval.
1. The document provides background information on a case study involving the launch of a new product called Monocryl Plus by Ethicon, a division of Johnson & Johnson Medical India.
2. Monocryl is an existing synthetic absorbable suture that has seen limited success in India. Monocryl Plus is a new innovation that adds an antibacterial coating.
3. The marketing manager, Amit Goswami, must prepare a quick launch plan for Monocryl Plus to present to management. As a consultant, you have been tasked to help develop this launch plan.
Access 2-healthcare company introduction deck - english - may 2018Access-2-Healthcare
Market Entry for Medical Technology / Medical Device companies, in Asia Pacific, Europe, US
#Commercialisation
#Healthcare
#Regulatory
#Quality
#SoftwareValidation / #Verification
#DueDiligence
#LicenseHolding
#Go-to-MarketStrategy
#MarketStudies
Introduction of Medimpex International LLC (English)Batnyam Maidarjav
Medimpex International is a leading medical equipment supplier in Mongolia that is celebrating its 10th anniversary. It provides important medical technology from global brands to Mongolian hospitals and aims to improve patient care. Medimpex supplies equipment, offers installation, training and maintenance services, and works to introduce the latest healthcare advances to Mongolia.
This document provides background information for developing a launch plan for Monocryl Plus, a new antibacterial coated synthetic absorbable suture. It discusses the suture market challenges facing Ethicon, including increased competition from low-cost producers. It also reviews the product details and performance of existing sutures like Vicryl and Monocryl. The consultant has been asked to develop a strategic launch plan for Monocryl Plus to drive adoption among surgeons and in new applications/markets.
GE Healthcare is a leading global medical technology and diagnostics company with over 100 years of innovation. It has over $17 billion in annual revenue, over 47,000 employees worldwide, and the world's largest medical imaging installed base of over 4 million systems. GE Healthcare is focused on precision health through digital and artificial intelligence solutions to drive better clinical decisions and health outcomes.
This document provides an overview of ANSYS Advantage magazine volume IX issue 1 from 2015. The summary includes:
1) ANSYS is dedicated to developing engineering simulation software to enable rapid and innovative product design. Their technology helps customers in demanding markets ensure product integrity and drive business success through innovation.
2) The magazine's lead article discusses how the healthcare industry is adopting simulation to address challenges like rising costs and the need for safe, reliable solutions. Simulation allows testing concepts virtually before physical prototypes.
3) Other articles describe how customers in fields like ophthalmology, medical devices, hearing aids, and more are using simulation to improve product performance and safety while reducing costs and time to market.
This document provides an overview of ANSYS Advantage magazine volume IX issue 1 from 2015. The summary includes:
1) ANSYS is dedicated to developing engineering simulation software to enable rapid and innovative product design and ensure products will succeed. They have over 40 years of experience working with demanding customers.
2) The magazine focuses on how various industries are using simulation for healthcare applications, including ophthalmology, medical devices, hearing aids, regulations, cardiology, and pharmaceuticals.
3) Short articles also discuss other applications of simulation like construction ventilation, fluid dynamics, antennas, nanoparticles, and GPU acceleration of CFD simulations.
The document discusses Draper & Dash, a UK-based healthcare technology company that provides data analytics applications and professional services to help healthcare organizations improve quality, safety, and efficiency. Some key points:
- Draper & Dash has over 22 clinical, operational and corporate healthcare data analytics applications.
- Their applications provide real-time visualization of key metrics like operating room utilization, mortality rates, and more to help hospitals identify areas for improvement.
- Over 40 hospitals in the UK, Australia, and Ireland use Draper & Dash's products, and the company expects revenue to triple in 2015 as it expands into new territories and releases new mobile applications.
- A case study highlights how The Royal Melbourne Hospital in
EliT Medical - complex solutions for your laboratory robertbul
EliT Medical (http://www.elitmedical.com/aboutus_en.html ) is a private Bulgarian company, established beginning of 2002.
We have in our product list a well-balanced portfolio of reagents and equipment, offering a complete solution for every clinical lab.
We offer to our customers and partners complex solutions and are focusing on providing problem-free and secure functioning of the customers’ lab.
EliT Medical is offering a complete consultancy services. Our team has a long market experience and the very good knowledge of the products in the diagnostics laboratory field. This is the base for us to provide our customers with decisions, that will help them organize their labs and activities in the most efficient, competitive and profitable way, will help them to offer their patients the most modern and effective diagnostics and fast and accurate results. We can help in the complete process –planning, establishing, equipping, organization and functioning of the diagnostic laboratory.
The products are of outstanding quality, manufactured by world-leading companies from Austria, Ireland, Japan, Poland, Switzerland, the USA etc.
We carefully chose and select our suppliers and partners, because for us the premium quality of the offered products and the satisfaction of our customers if the first priority in our everyday business.
Our company aim is to improve continuously the quality of our work at more competitive price levels. This, together with our already build relations and leading market position are the premises for the attractive prices and customers oriented policy, which we are able to offer.
Our portfolio includes a complex equipment, reagents and consumables for clinical laboratories in hospitals, laboratory-diagnostic units and private medical centers. We offer fully automated biochemical and clinical chemistry diagnostic systems; automated immunological analyzers; automatic 3-diff and 5-diff hematology instruments; automated systems for ion-selective analysis; semi-automatic and automatic instruments for coagulation; instruments and tests for POC and express diagnostics, etc., as well as high quality diagnostic reagents, quality test tubes for closed blood collection system, consumables, spare parts and full servicing for the installed equipment. Our clinical chemistry portfolio includes a full range of routine and sophisticated analyzers covering the complete range – from small – medium to high capacity instruments, also able to perform immunochemistry tests essential for accurate diagnosis. For haematology lab, we provide an innovative technology for the most popular 3-Diff and advanced 5-Diff systems supported by Swiss analyzers.
We also offer general lab equipment as centrifuges and microscopes from premium European producers.
You can be among our friends and partners!
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
2. Introduction of UEG
Medical and its business
mission, vision and core
values
2
A brief on Universal
Enterprises Group
1
ABOUT US UEG MEDICAL
Introduction of UEG
Medical products and
certifications
3
OUR PRODUCT
Why UEG Medical is
trusted partner? What will
partners benefit from us?
4
PARTNERS WITH US
@Copyright Universal Enterprises Group Co. Ltd. 2017